Exploiting Inhibitory Siglecs to Combat Food Allergies
Abstract
During year one of this Expansion Award, we have generated novel data for targeting CD22 on B cells and CD33 on mast cells and basophils to abrogate food allergies. Under Specific Aim 1, we demonstrated that STALs targeting memory B cells can be used to suppress IgE production, thus preventing allergic reactions upon allergen challenge. We showed this effect in mice adoptively transferred mouse memory B and T cells, as well as in a humanized mouse model using human PBMCs transferred into NSG mice. This work was carried out with three major peanut allergens, Ara h 1, 2, and 3 and was recently published in the Journal of Allergy and Clinical Immunology (Impact Factor 14.29). Under Specific Aim 2, we have demonstrated that antigenic nanoparticles with CD33L suppress anaphylaxis in allergen sensitized mice, and have utilized a novel approach by conjugating human CD33L directly to anti-human IgE, without the use of liposomes for scaffolding. This molecule has proven effective for the inhibition of human basophil degranulation using the whole blood BAT assay. Overall, our results continue to push us forward, demonstrating translational applications for targeting human CD22 and CD33 in various model systems.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1194699
Entities
People
- James C. Paulson
- Michael Kulis
Organizations
- Scripps Research
- University of North Carolina at Chapel Hill